Euroapi's IPO is becoming clearer.
Despite the instability of the markets, Sanofi announced on Friday that the listing of its subsidiary specializing in the production of active ingredients - these substances which give drugs their therapeutic properties - will take place in the first half of 2022.
Read also
Paul Hudson: “Sanofi could be the big winner in messenger RNA”
On this occasion, the French State should become a shareholder of Euroapi, this company created in 2021 to allow Sanofi to partially withdraw from the activity.
The entity thus brings together six of its eleven factories manufacturing active ingredients.
"The State plans to acquire 12% of the capital, for a maximum amount of 150 million euros from Sanofi to become a long-term reference shareholder"
, specifies the first French laboratory.
In detail, it is French Tech Souveraineté, a fund managed by the public bank Bpifrance, which will make the investment.
This fund was created at the start of the Covid crisis to support start-ups in difficulty.
It therefore changes its purpose today.
In December, the president of Euroapi, Karl Rotthier, explained that he was in discussions
"with many potential investors"
, including Bpifrance or the European Investment Bank (EIB).
Which is not surprising.
The Covid crisis has caused many tensions in the supply of active ingredients and shone the spotlight on the need to reduce dependence on China and India, the two giants of the sector.
The European public authorities - including France - have since taken up this subject of health sovereignty.
As announced, Sanofi will retain 30% of Euroapi's capital.
The company employs 3,350 people and expects to achieve a turnover of 1 billion euros in 2022. This makes it one of the main producers of active ingredients on the Old Continent.
Euroapi intends to develop and plans to invest 580 million euros by 2025, around half of which in France.
